Subtypes in pancreatic ductal adenocarcinoma based on niche factor dependency show distinct drug treatment responses.

Our findings suggest that CAFs maintain the differentiated PDAC phenotype through secreting niche factors and induce distinct drug responses. These results may lead to the development of novel subtype-based therapeutic strategies.